Referencias: guía detallada del cáncer de seno
Abeloff MD, Wolff AC, Weber BL, et al. Cancer of the Breast. In: Abeloff MD, Armitage JO, Lichter AS, et al, eds. Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008: 1875–1943.
American Cancer Society. Cancer Facts and Figures 2015. Atlanta, Ga: American Cancer Society; 2015.
American Joint Committee on Cancer. Breast. In: AJCC Cancer Staging Manual, 7th ed. New York: Springer; 2010: 347–369.
Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004 Apr 14;291(14):1701−1712.
Anderson GL, Clebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012 May;13(5):476−486. Epub 2012 Mar 7.
Avis N, Crawford S, Manuel J, et al. Quality of life among younger women with breast cancer. J Clin Oncol. 2005;23:3322–3330.
Azim HA Jr, Santoro L, Pavlidis N, Gelber S, Kroman N, Azim H, Peccatori FA. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer. 2011 Jan;47(1):74-83. Epub 2010 Oct 11.
Bachelot T, Bourgier C, Cropet C, et al. Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study. J Clin Oncol. 2012 Aug 1;30(22):2718−2724. Epub 2012 May 7.
Bahcall O. Common variation and heritability estimates for breast, ovarian and prostate cancers. Nature Genetics. Accessed at www.nature.com/icogs/primer/common-variation-and-heritability-estimates-for-breast-ovarian-and-prostate-cancers/ on May 30, 2013.
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 9;366(6):520−529. Epub 2011 Dec 7.
Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12;366(2):109−119. Epub 2011 Dec 7.
Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009 Jun 1;27(16):2630−2637. Epub 2009 Apr 20.
Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419–427.
Bertelsen L, Mellemkjaer L, Christensen J, Rawal R, Olsen JH. Age-specific incidence of breast cancer in breast cancer survivors and their first-degree relatives. Epidemiology. 2009;20:175-180.
Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010 Mar 1;28(7):1124−1130. Epub 2010 Feb 1.
Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992;326:781-785.
Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol. 2005;23:7350–7360.
Briot K, Tubiana-Hulin M, Bastit L, et al. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat. 2010 Feb;120(1):127-34. Epub 2009 Dec 25.
Brown LM, Chen BE, Pfeiffer RM, et al. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat. 2007;106:439-451.
Burstein HJ, Harris JR, Morrow M. Malignant tumors of the breast. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011:1401–1456.
Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010 Mar 10;28(8):1301-1307. Epub 2010 Feb 8.
California Environmental Protection Agency. Health Effects of Exposure to Environmental Tobacco Smoke. June 2005. Accessed at www.oehha.ca.gov/air/environmental_tobacco/pdf/app3partb2005.pdf on November 7, 2011.
Chen L, Malone KE, Li CI. Bra Wearing Not Associated with Breast Cancer Risk: A Population-Based Case-Control Study. Cancer Epidemiol Biomarkers Prev. 2014 Sep 5. [Epub ahead of print]
Chen LC, Weiss NS, Newcomb P, et al. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287:734–741.
Chung AP, Sacchini V. Nipple-sparing mastectomy: where are we now? Surg Oncol. 2008 Dec;17(4):261-266.
Ciatto S, Houssami N, Bernardi D, et al. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. Lancet Oncol. 2013 Jun;14(7):583-9. Epub 2013 Apr 25.
Clarke M, Collins R, Darby S, et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365:1687–1717.
Coleman RE, Winter MC, Cameron D, et al; AZURE (BIG01/04) Investigators. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer. 2010 Mar 30;102(7):1099-1105. Epub 2010 Mar 16.
Coleman RE, Marshall H, Cameron D, et al. Breast Cancer Adjuvant Therapy with Zoledronic Acid. N Engl J Med. 2011 Oct 13;365(15):1396-1405. Epub 2011 Sep 25.
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996 Jun 22;347(9017):1713-1727.
Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001;358:1389-1399.
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002 Jul 20;360(9328):187-195.
Curtis RE, Ron E, Hankey BF, Hoover RN. New Malignancies Following Breast Cancer. In: Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. (eds). New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute. NIH Publ. No. 05-5302. Bethesda, MD, 2006. Accessed on 4/18/2014 at http://seer.cancer.gov/archive/publications/mpmono/MPMonograph_complete.pdf.
Darbre PD, Aljarrah A, Miller WR, et al. Concentrations of parabens in human breast tumours. J Appl Toxicol. 2004;24:5–13.
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.
Dillon DA, Guidi AJ, Schnitt SJ. Pathology of invasive breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 4th ed. Philadelphia, Pa: Lippincott-Williams & Wilkins; 2010: 374−407.
Dorval M, Guay S, Mondor M, et al. Couples who get closer after breast cancer: Frequency and predictors in a prospective investigation. J Clin Oncol. 2005;23:3588–3596.
Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998 May 16;351(9114):1451-67.
Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;366:2087–2106.
Farvid MS, Cho E, Chen WY, Eliassen AH, Willett WC. Dietary protein sources in early adulthood and breast cancer incidence: prospective cohort study. BMJ. 2014;348:g3437.
FDA briefing information, Avastin (bevacizumab), for the July20, 2010 Meeting of the Oncology Drugs Advisory Committee. Accessed at http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm219223.htm on July 20, 2010.
Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–1662.
Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009 Apr 1;27(10):1564–1571. Epub 2009 Feb 23.
Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009 Jul 9;361(2):123–134. Epub 2009 Jun 24.
Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013 Apr;14(4):297-305. Epub 2013 Mar 11.
Gärtner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009 Nov 11;302(18):1985−1992.
Giuliano AE, Hunt KK, Ballman KV, et al. Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis. JAMA. 2011;305(6):569-575.
Giusti RM, Iwamoto K, Hatch EE. Diethylstilbestrol revisited: a review of the long-term health effects. Ann Intern Med. 1995 May 15;122(10):778-788.
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Austrian Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008 Sep;9(9):840–849. Epub 2008 Aug 19.
Goodwin PJ, Ennis M, Pritchard KI, et al. Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast Cancer. J Clin Oncol. 2009 May 18.
Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381−2391.
Gray RG, Rea D, Handley K, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol (Meeting Abstracts) June 2013 vol. 31 no. 18_suppl 5.
Hamajima N, Hirose K, Tajima K, et al. Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002 Nov 18;87(11):1234-1245.
Heiss G, Wallace R, Anderson GL, et al, WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299:1036-1045.
Helvie MA. Imaging analysis: mammography. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 4th ed. Philadelphia, Pa: Lippincott-Williams & Wilkins; 2010: 116−130.
Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer -- is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363:453–455.
Holmes MD, Chen WY, Feskanich D, et al. Physical activity and survival after breast cancer diagnosis. JAMA. 2005;293:2479–2486.
Hoover RN, Hyer M, Pfeiffer RM, et al. Adverse health outcomes in women exposed in utero to diethylstilbestrol. New Engl J Med. 2011;365:1304−1314.
Houssami N, Hayes DF. Review of preoperative magnetic resonance imaging (MRI) in breast cancer: should MRI be performed on all women with newly diagnosed, early stage breast cancer? CA Cancer J Clin. 2009 Sep-Oct;59(5):290-302. Epub 2009 Aug 13.
Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
Kabat GC, Cross AJ, Park Y, et al. Meat intake and meat preparation in relation to risk of postmenopausal breast cancer in the NIH-AARP diet and health study. Int J Cancer. 2009 May 15;124(10):2430−2435.
Kabat GC, Kim M, Adams-Campbell LL, et al; WHI Investigators. Longitudinal study of serum carotenoid, retinol, and tocopherol concentrations in relation to breast cancer risk among postmenopausal women. Am J Clin Nutr. 2009 Jul;90(1):162−169.
King MC, Wieand S, Hale K, et al. National Surgical Adjuvant Breast and Bowel Project. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286:2251-2256.
Kushi LH, Doyle C, McCullough M, et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012;62:30-67.
Lawenda BD, Mondry TE, Johnstone PA. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin. 2009 Jan-Feb; 59(1):8–24.
Li CI, Beaber EF, Chen Tang MT, Porter PL, Daling JR, Malone KE. Effect of Depo-Medroxyprogesterone Acetate on Breast Cancer Risk among Women 20 to 44 Years of Age. Cancer Res. 2012 Apr 15;72(8):2028-2035. Epub 2012 Feb 27.
Marshall H, Gregory W, Bell R, et al. Adjuvant therapy with zoledronic acid (AZURE-BIG 01/04): The influence of menopausal status and age on treatment effects. J Clin Oncol. 2012; 30(suppl; abstr 502)
McCloskey E, Paterson A, Kanis J, et al. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. Eur J Cancer. 2010 Feb;46(3):558-565. Epub 2009 Dec 22.
McTiernan A, Kooperberg C, White E, et al. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA. 2003; 290:1331–1336.
Mirick DK, Davis S, Thomas DB. Antiperspirant use and the risk of breast cancer. J Natl Cancer Inst. 2002;94:1578–1580.
Moskovitz AH, Anderson BO, Yeung RS, Byrd DR, Lawton TJ, Moe RE. Axillary web syndrome after axillary dissection. Am J Surg. 2001 May;181(5):434−439.
Moyer VA on behalf of the U.S. Preventive Services Task Force. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2014 Feb 18;160(4).
National Cancer Institute. Genetics of Breast and Ovarian Cancer (PDQ®). 7/25/2013. Accessed at http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional on 8/16/2013.
National Cancer Institute Fact Sheets. Antiperspirants/Deodorants and Breast Cancer. 1/4/2008. Accessed at http://www.cancer.gov/cancertopics/factsheet/Risk/AP-Deo on August 16, 2013.
National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Breast Cancer. Version 3.2014. Accessed at www.nccn.org on June 10, 2014.
National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2012. Accessed at www.nccn.org on 8/23/12
Nattinger A. Variation in the choice of breast-conserving surgery or mastectomy: Patient or physician decision making? J Clin Oncol. 2005;23:5429–5431.
Olsson HL, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer. 2003; 97:1387–1392.
Pagani O, Regan MM, Walley BA, et al. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. N Engl J Med.2014 Jun 1. [Epub ahead of print]
Patil R, Clifton GT, Holmes JP, et al. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial. J Am Coll Surg. 2010 Feb;210(2):140-147. Epub 2009 Dec 22.
Pierce JP, Patterson RE, Senger CM, Flatt SW, Caan BJ, Natarajan L, Nechuta SJ, Poole EM, Shu XO, Chen WY. Lifetime cigarette smoking and breast cancer prognosis in the After Breast Cancer Pooling Project. J Natl Cancer Inst. 2014 Jan;106(1):djt359. Epub 2013 Dec 7.
Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26:2568–2581.
Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616–1622.
Rosenberg RD, Yankaskas BC, Abraham LA, et al. Performance benchmarks for screening mammography. Radiology. 2006 Oct;241(1):55-66.
Ross J, Hatzis C, Symmans F, et al. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008;13:477–493.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321-333.
Santen RJ, Mansel R. Benign breast disorders. N Engl J Med. 2005;353:275-285.
Saslow D, Boetes C, Burke W, et al for the American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75-89. Available at: http://caonline.amcancersoc.org/cgi/content/full/57/2/75. Accessed July 17, 2008.
Schnitt SJ, Collins LC. Pathology of benign breast disorders. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2010:69-85.
Sickles EA. The use of breast imaging to screen women at high risk for cancer. Radiol Clin North Am. 2010 Sep;48(5):859-78.
Simpson PT, Reis-Filho JS, Lakhani SR. Lobular Carcinoma In Situ: Biology and Pathology. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins. 2010: 333-340.
Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB. Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand studies. JAMA. 1995 Mar 8;273(10):799-804.
Smith GL, Xu Y, Buchholz TA, Giordano SH, Jiang J, Shih YC, Smith BD. Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. JAMA. 2012 May 2;307(17):1827-1837.
Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. 2003 May-Jun;53(3):141-169.
Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol. 2003;21:1195-1204.
Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013 May 15;105(10):701-10. Epub 2013 May 2.
Stopeck AT, Lipton A, Body JJ, et al. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. J Clin Oncol. 2010 Dec 10;28(35):5132-5139. Epub 2010 Nov 8.
The American College of Radiology BI-RADS® ATLAS and MQSA: Frequently Asked Questions. 11/29/12. Accessed at http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/BIRADS/BIRADSFAQs.pdf on February 6, 2013.
Thompson D, Easton D, and The Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94:1358–1365.
US Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. 2006. Accessed at www.surgeongeneral.gov/library/secondhandsmoke/ on November 3, 2011.
US Food and Drug Administration. Bio-Identicals: Sorting Myths from Facts. Accessed at http://www.fda.gov/forconsumers/consumerupdates/ucm049311.htm on 2/14/2012.
Vadivelu N, Schreck M, Lopez J, et al. Pain after mastectomy and breast reconstruction. Am Surg. 2008. 74:285–296.
Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783-91. Epub 2012 Oct 1.
Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. The postmastectomy pain syndrome: An epidemiological study on the prevalence of chronic pain after surgery for breast cancer. Br J Cancer. 2008. 99:604–610.
Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–2741.
Vogel VG, Costantino JP, Wickerham DL, et al. Update of theNational Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (PhilaPa). 2010 Jun;3(6):696-706. Epub 2010 Apr 19.
Walker EM, Rodriguez AI, Kohn B, et al. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol. 2010 Feb 1;28(4):634-640.
Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002;94:1143–1150.
Winer EP, Carey LA, Dowsett M, Tripathy D. Beyond anatomic staging: Is it time to take a leap into the molecular era? American Society of Clinical Oncology Educational Book. Alexandria, Va: American Society of Clinical Oncology; 2005.
Wolff AC, Blackford AL, Visvanathan K, et al. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J Clin Oncol. 2015 Feb 1;33(4):340-8. Epub 2014 Dec 22.
Fecha de última actualización: 10/22/2014
Fecha de último cambio o revisión: 02/26/2015